Answers are grounded in this paper and cite their sources.
Breast cancer (BC) remains a leading cause of cancer-related mortality, driven largely by tumor heterogeneity, clonal evolution, and therapeutic resistance. Tissue biopsy, while the diagnostic gold standard, offers only a static snapshot of a constantly evolving disease, and repeated sampling is often impractical, particularly in metastatic settings. Liquid biopsy has emerged as a minimally invasive alternative capable of capturing this evolving biology in real time through circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs). This review examines the biological features, analytical technologies, and clinical applications of these analytes in BC, with particular attention to two rapidly evolving areas. First, we discuss how artificial intelligence and machine learning are being applied to multi-analyte liquid biopsy data, from methylation- and fragmentomics-based classifiers for early detection to models integrating ctDNA and CTC information for resistance profiling and treatment-response prediction, while critically examining current limits in clinical validation and interpretability. Second, we address the role of serial ctDNA monitoring in the neoadjuvant setting, where it can refine risk stratification beyond pathologic complete response and identify candidates for early therapeutic escalation, reflected in intervention trials now testing this approach prospectively. We also cover established roles of these analytes in treatment monitoring, minimal residual disease (MRD) detection, resistance tracking, and metastatic disease management, alongside persistent barriers to routine adoption, including limited early-stage ctDNA shedding, clonal hematopoiesis, and inconsistent analytical standardization. As these technologies mature, liquid biopsy is poised to move from a prognostic tool toward one that guides personalized treatment in BC. Not applicable. This article is a narrative review. Liquid biopsy enables longitudinal profiling of breast cancer biology. ctDNA, CTCs, and EVs provide complementary biological information. ctDNA detection can precede breast cancer relapse by approximately 10–12 months. PADA-1 showed improved PFS with plasma-guided ESR1-directed switching. Multi-analyte approaches may improve prediction beyond single biomarkers.
No takes yet. Share an insight, caveat, or question.
Gholami et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: